{"nctId":"NCT00981045","briefTitle":"Evaluation of Efficacy and Safety of Ferric Carboxymaltose (FCM) in Patients With Iron Deficiency Anemia and Impaired Renal Function","startDateStruct":{"date":"2009-08"},"conditions":["Iron Deficiency Anemia","Impaired Renal Function"],"count":2561,"armGroups":[{"label":"Ferric Carboxymaltose (FCM)","type":"EXPERIMENTAL","interventionNames":["Drug: Ferric Carboxymaltose (FCM)"]},{"label":"Iron Sucrose (Venofer)","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Iron Sucrose (Venofer)"]}],"interventions":[{"name":"Ferric Carboxymaltose (FCM)","otherNames":[]},{"name":"Iron Sucrose (Venofer)","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Male or female subjects \\> or = to 18 years of age.\n* Chronically impaired renal function.\n* Screening visit central laboratory hemoglobin \\< or = to 11.5 g/dL.\n* Screening ferritin \\< or = to 100 ng/mL or \\< or = to 300 when transferrin saturation (TSAT) is \\< or = to 30%.\n* If on an erythropoiesis stimulating agent(ESA) a stable dose (+/- 20%) for 4 weeks prior to randomization.\n\nExclusion Criteria:\n\n* Known hypersensitivity reaction to any component of ferric carboxymaltose (FCM) or Venofer.\n* Previously randomized in a clinical study of Ferric Carboxymaltose (FCM).\n* Requires dialysis for treatment of chronic kidney disease OR is being considered for initiation of dialysis during the time period of this trial.\n* No evidence of iron deficiency.\n* Any non-viral infection.\n* AST or ALT at screening as determined by central labs greater than 1.5 times the upper limit of normal.\n* Known positive hepatitis with evidence of active disease.\n* Received an investigational drug within 30 days of screening.\n* Alcohol or drug abuse within the past 6 months.\n* Hemochromatosis or other iron storage disorders.\n* Estimated life expectancy of less than 6 months, or for cancer patients, an ECOG Performance Status greater than 1.\n* Any other laboratory abnormality, medical condition or psychiatric disorder which in the opinion of the investigator would put the subject's disease management at risk or may result in the subject being unable to comply with study requirements.\n* Pregnant or sexually-active female subjects who are not willing to use an acceptable form of contraception.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Mean Change From Baseline to the Highest Observed Hemoglobin Any Time From Baseline to End of Study.","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.13","spread":"1.044"},{"groupId":"OG001","value":"0.92","spread":"0.917"}]}]}]},{"type":"PRIMARY","title":"Proportion of Subjects Experiencing at Least One Event in the Primary Composite Safety Endpoint in the Randomized Population.","description":"The primary composite safety endpoint was defined as death due to any cause, nonfatal myocardial infarction, nonfatal stroke, unstable angina requiring hospitalization or medical intervention, arrhythmias, protocol-defined hypersensitive events, and protocol-defined hyposensitive events.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"175","spread":null},{"groupId":"OG001","value":"156","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":202,"n":1276},"commonTop":["Hypertension","Nausea"]}}}